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Mapping out fat profits 
Millennium 
Pharmaceuticals, Inc. 
Exercise and diet are all very well, 
but for the pill-happy and increasingly 
obese Western world, a drug to cure 
the fat woes is a delicious prospect. 
Millennium Pharmaceuticals, Inc., of 
Cambridge, Massachusetts, USA, is 
relying on genetics and corporate 
partnerships in a high stakes race to 
capitalize on this huge market. 
“The whole idea of 
Millennium,” says Jeffrey Thomas, 
the Project Leader for Diabetes at 
Millennium, “is that now at last with 
the genome project and automation 
. . . we can address common diseases. 
The amount of information we can 
bring to bear on the diseases makes 
the complexity more tractable.” And 
the biggest of the complex diseases 
is obesity. 
In the beginning there was leptin 
The explosion in obesity research 
began in 1994, when Jeff Friedman 
of Rockefeller University in New 
York discovered leptin. Fat cells 
release leptin into the bloodstream, 
and the protein then signals to the 
brain that there is cellulite available, 
so that it decreases food intake and 
increases energy expenditure. The 
addition of leptin to normal mice 
makes them skinnier. 
Amgen Inc. leapt on the leptin 
discovery in 1995, licensing the use 
of the protein from Rockefeller 
University. Millennium and 
Hoffman-La Roche, became 
involved later the same year with the 
discovery of the flip side of the 
equation, the cell-surface receptor 
for leptin. The Millennium/Roche 
team, led by Louis Tartaglia, the 
Director of Metabolic Diseases at 
Millennium, found that labeled 
leptin bound to the choroid plexus in 
mouse brains. By dissecting out this 
tiny organ from 300 mouse brains, 
the scientists were able to construct a 
cDNA expression library, which they 
then screened for leptin binding. 
The protein that they identified is a 
single membrane-spanning receptor, 
most closely related to the signal- 
transducing component of the 
receptor for several cytokines. The 
Millennium group and two groups 
from Rockefeller later confirmed that 
the receptor was the product of the 
mouse diabetes (db) gene. As with mice 
mutant for the leptin gene (obese or 
ob), mice mutant for db are fat. 
Fat control in the brain 
Given that weight loss leads to 
decreased leptin production, and 
thus weight gain, the next focus for 
research was in the brain. What 
happens after the leptin signal is 
received? Late last year, a group led 
by Richard Palmiter at the 
University of Washington at Seattle 
found that deleting the gene for 
neuropeptide Y (NPY) made ob mice 
less obese, implicating NPY in the 
response to starvation and lowered 
leptin levels. 
Millennium tackled this problem 
using genetics and a fat, yellow 
mouse called agod The agouti 
protein is normally restricted to hair 
follicles, where it antagonizes the 
melanocortin-1 receptor and so 
induces a switch in pigment 
production. In ago& mice, the agouti 
protein is made throughout the 
mouse. The Millennium/Roche team 
and a group from the Oregon Health 
Sciences University led by Roger 
Cone showed that, in this situation, 
the agouti protein can also 
antagonize the melanocortin-4 
receptor (MC4-R), thus causing 
obesity. Deletion of the MC4-R gene 
results in late-onset obesity. In 
contrast to NPY, the MC4-R may be 
involved in the response to high 
leptin levels and weight gain. 
To market, to market 
While Amgen has begun trials with 
leptin, Millennium has a patent for 
therapies that target the leptin 
receptor (and presumably the lawyers 
to defend any area of overlap with 
Amgen). Tartaglia is most excited by 
this target. “If we were to succeed [in 
finding] a direct leptin receptor 
agonist,” he says, “I think we would 
make it into clinical trials.” But he 
says that Millennium remains 
interested in the MC4-R project, 
because it has historically been easier 
to find agonists of seven- 
transmembrane receptors (such as the 
MC4-R) than single-transmembrane 
receptors (such as the leptin receptor). 
The choice of therapeutic target 
is not necessarily driven by the cause 
of the disease. There is a disputed 
linkage between human obesity and 
mutations in the P3-adrenergic 
receptor, and some obese people 
appear to have more unbound 
circulating leptin, but little is known 
about the actual cause of obesity in 
the majority of humans. “In a way I 
think it’s irrelevant,” says Tartaglia. 
“People are going to be obese for a 
number of reasons, and some for a 
complex mixture of reasons. Our job 
is to identify important pathways and 
super-stimulate them.” 
Using the same reasoning, other 
companies are throwing the kitchen 
sink at obesity. Two drugs have 
recently been approved for marketing 
in the United States. Orlistat, 
developed by Roche Biosciences, 
catches the offender at the starting 
gate, inhibiting gastric lipase and so 
reducing fat absorption. Redux, or 
dexfenfluramine, boosts levels of the 
neurotransmitter serotonin, so the 
patient feels full (the serotonin 
receptor 2c regulates satiety). Both 
drugs have side effects: for Orlistat 
there are unpleasant consequences 
from unabsorbed fat, and Redux 
causes fatigue and insomnia. 
Other companies are examining a 
handful of gut peptides that signal 
satiety by a variety of mechanisms, 
and leptin mimetics and NPY-1 
antagonists are also being developed. 
ObeSys is even testing polyclonal 
antibodies to fat cells, although thus 
far only for the production of the 
perfect pork chop. 
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Spinning the metabolic wheels 
One of Millennium’s alternative 
approaches to obesity involves 
redirecting metabolic energy towards 
heat production. At the center of the 
heat-generating machinery are the 
uncoupling proteins, which allow 
protons to flow down the proton 
gradient across the mitochondrial 
inner membrane without generating 
ATI? UCP, the first uncoupling 
protein to be isolated, is unlikely to 
be a useful target for human 
therapies. It is found only in brown 
fat, which is common in rode’nts but 
lost by humans one year after! birth. 
Millennium have patented the 
use of a second uncoupling protein, 
UCPH, which they isolated based on 
its homology to UCP. Expression of 
UCPH is toxic to yeast only if the 
yeast are using aerobic respiration, 
and UCPH disrupts the proton 
gradient across the inner 
mitochondrial membrane. This latter 
effect was measured using a charged 
dye, DiOC,, which inserts in the 
membrane only if there is a charge 
gradient across the membrane. 
Tartaglia admits that UCPH 
stimulation may create problems in 
temperature regulation, but he 
believes that other temperature 
regulation systems will kick in, and 
that the increase in UCPH activity 
needed to burn off fat will cause a 
negligible increase in core body 
temperature. 
UCPH may be an ideal drug 
target. Various fatty acids are known 
to be positive regulators of the 
protein’s activity, says Tartaglia, so 
UCPH “is designed to accept 
positive regulation by small 
molecules.” 
The consequences of obesity: diabetes 
The primary risk factors for late-onset 
(non-autoimmune, type II) diabetes 
are age and obesity. The exact nature 
of the connection between obesity 
and diabetes is unknown, but a 
substance produced by fat cells 
probably induces insulin resistance in 
target tissues like muscle. Initially, the 
pancreas keeps up by producing more 
insulin; later it is overwhelmed and 
diabetes results. 
The incidence of diabetes has 
been rising in the Western world, 
mirroring the rise in obesity. But there 
are also genetic factors, and it is those 
factors that have piqued Millennium’s 
interest. The high-throughput 
genotyping ability of Millennium was 
put to use in a recent collaborative 
study of an isolated Finnish 
population (the subjects speak 
Swedish, while the surrounding 
population is Finnish-speaking). The 
study identified a linkage between 
low insulin secretion and a region on 
chromosome 12. This region includes 
the gene that causes MODYS, a rare, 
dominant, early-onset form of 
diabetes. It is not yet clear whether 
MODY3, a widely expressed 
transcription factor, and the new gene, 
NIDDMZ, are one and the same. The 
company has also announced the 
mapping of another, distinct gene for 
diabetes, although they are not 
disclosing the identity or location of 
this gene. 
To track down a gene involved in 
a complex trait, human geneticists 
need a large number of variable 
(polymorphic) markers. Millennium 
most commonly uses microsattelite 
markers, variable simple sequence 
repeats like (CA), (n > 10) that are 
susceptible to mutation by slippage of 
the DNA replication apparatus. PCR 
amplification of the markers using 
surrounding simple sequence primers 
gives a large quantity of DNA for size 
comparisons. For a complex trait, 
400-500 markers (one marker every 
8-10cM) are typed for each of 
1000-2000 individuals. 
This is no small feat, and 
complexities arise. “Ideally we want a 
box where we put DNA in one end 
and get a genotype out the other,” 
says Thomas. But DNA duplications 
and ambiguities mean that human 
intervention is inevitable. Millennium 
and other high-throughput outfits are 
now looking at using point mutations 
as alternative markers. Although there 
are only two possible states (mutated 
or not), systems based on this 
hybridization technology are much 
more amenable to automation. 
The human genome project will 
also help in the gene hunting. 
“Ultimately it’s going to eliminate a 
step in the process,” says Thomas. 
The initial mapping will still be 
necessary, but then the researchers 
will skip directly to the correlation of 
the disease with mutations in genes, 
without first having to define the 
existence of those genes. 
Atherosclerosis and other matters 
Cardiovascular disease is another 
focus for Millennium. In collaboration 
with Michael Gimbrone of Brigham 
and Women’s Hospital in Boston, 
Millennium scientists have isolated 
genes that may be involved in 
atherosclerotic plaque development. 
The genes are induced by culturing 
endothelial cells in a flow cell 
designed by Gimbrone. In the flow 
cell, uniform shear stresses mimic 
blood flow typical of plaque-free 
areas, and turbulent stresses mimic 
the conditions in plaque-rich areas. 
For each of the areas of research 
mentioned above, and several others 
that are less well developed, 
Millennium has entered into 
collaborative agreements for drug 
development. The collaborators 
include Hoffman-La Roche (obesity 
and diabetes), Eli Lilly 
(atherosclerosis), Wyerth Ayerst 
(psychiatric disorders) and Astra AB 
(asthma and allergies). 
With these collaborations, 
Millennium can hand off many of 
the expensive and risky stages of 
drug discovery. But even sticking to 
target discovery is not foolproof. 
Although Millennium can estimate 
how much genetics contributes to a 
disease, it is impossible to get good 
estimates of how common a disease 
gene will be in a population, and 
how many fold increased risk it will 
confer. Fat profits, it seems, are 
never a sure thing. 
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